SEC Form 4 · accession 0001144204-18-062651
BRAINSTORM CELL THERAPEUTICS INC. · BCLI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Uri Yablonka
Officer — EVP and Chief Business Officer · Director
Period of report
Nov 30, 2018
Accepted (ET)
Nov 30, 2018 · 5:03 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001137883
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $0.75 | Nov 30, 2018 | A | 13,333 | A | Dec 30, 2018 | Nov 30, 2028 | Common Stock | 13,333 | 13,333 | D |
Explanation of responses
- F1Option vests and becomes exercisable in 12 consecutive, equal monthly installments commencing on December 30, 2018 until fully vested and exercisable on November 30, 2019, provided that the reporting person remains a director of Brainstorm Cell Therapeutics on each vesting date.